Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance.
Sobas MA, Turki AT, Ramiro AV, Hernández-Sánchez A, Elicegui JM, González T, Melchor RA, Abáigar M, Tur L, Dall'Olio D, Sträng E, Tettero JM, Castellani G, Benner A, Döhner K, Thiede C, Metzeler KH, Haferlach T, Damm F, Ayala R, Martínez-López J, Mills KI, Sierra J, Lehmann S, Porta MGD, Mayer J, Reinhardt D, Medina RV, Schulze-Rath R, Barbus M, Hernández-Rivas JM, Huntly BJP, Ossenkoppele G, Döhner H, Bullinger L. Sobas MA, et al. Among authors: tettero jm. Haematologica. 2024 Nov 7. doi: 10.3324/haematol.2024.285805. Online ahead of print. Haematologica. 2024. PMID: 39506894 Free article.
Acute myeloid leukemia: does sex matter?
Tettero JM, Cloos J, Bullinger L. Tettero JM, et al. Leukemia. 2024 Nov;38(11):2329-2331. doi: 10.1038/s41375-024-02435-z. Epub 2024 Oct 14. Leukemia. 2024. PMID: 39402216 Free PMC article. Review. No abstract available.
Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study.
Hernández-Sánchez A, González T, Sobas M, Sträng E, Castellani G, Abáigar M, Valk PJM, Villaverde Ramiro Á, Benner A, Metzeler KH, Azibeiro R, Tettero JM, Martínez-López J, Pratcorona M, Martínez Elicegui J, Mills KI, Thiede C, Sanz G, Döhner K, Heuser M, Haferlach T, Turki AT, Reinhardt D, Schulze-Rath R, Barbus M, Hernández-Rivas JM, Huntly B, Ossenkoppele G, Döhner H, Bullinger L. Hernández-Sánchez A, et al. Among authors: tettero jm. Leukemia. 2024 Sep;38(9):1929-1937. doi: 10.1038/s41375-024-02333-4. Epub 2024 Jul 4. Leukemia. 2024. PMID: 38965370 Free PMC article.
Covering Hierarchical Dirichlet Mixture Models on binary data to enhance genomic stratifications in onco-hematology.
Dall'Olio D, Sträng E, Turki AT, Tettero JM, Barbus M, Schulze-Rath R, Elicegui JM, Matteuzzi T, Merlotti A, Carota L, Sala C, Della Porta MG, Giampieri E, Hernández-Rivas JM, Bullinger L, Castellani G; with the HARMONY Healthcare Alliance Consortium. Dall'Olio D, et al. Among authors: tettero jm. PLoS Comput Biol. 2024 Feb 2;20(2):e1011299. doi: 10.1371/journal.pcbi.1011299. eCollection 2024 Feb. PLoS Comput Biol. 2024. PMID: 38306404 Free PMC article.
Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML.
Tettero JM, Buisman Y, Ngai LL, Bachas C, Gjertsen BT, Kelder A, van de Loosdrecht AA, Manz MG, Pabst T, Scholten W, Ossenkoppele GJ, Cloos J, de Leeuw DC. Tettero JM, et al. Hemasphere. 2023 Nov 21;7(12):e981. doi: 10.1097/HS9.0000000000000981. eCollection 2023 Dec. Hemasphere. 2023. PMID: 38026789 Free PMC article. No abstract available.
Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry.
Tettero JM, Dakappagari N, Heidinga ME, Oussoren-Brockhoff Y, Hanekamp D, Pahuja A, Burns K, Kaur P, Alfonso Z, van der Velden VHJ, Te Marvelde JG, Hobo W, Slomp J, Bachas C, Kelder A, Nguyen K, Cloos J. Tettero JM, et al. Cytometry B Clin Cytom. 2023 Nov;104(6):426-439. doi: 10.1002/cyto.b.22144. Epub 2023 Sep 28. Cytometry B Clin Cytom. 2023. PMID: 37766649 Free article.
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival.
Tettero JM, Ngai LL, Bachas C, Breems DA, Fischer T, Gjertsen BT, Gradowska P, Griskevicius L, Janssen JJWM, Juliusson G, Maertens J, Manz MG, Pabst T, Passweg J, Porkka K, Valk PJM, Löwenberg B, Ossenkoppele GJ, Cloos J. Tettero JM, et al. Haematologica. 2023 Oct 1;108(10):2794-2798. doi: 10.3324/haematol.2022.282639. Haematologica. 2023. PMID: 37021540 Free PMC article. No abstract available.
Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trial.
Ngai LL, Hanekamp D, Janssen F, Carbaat-Ham J, Hofland MAMA, Fayed MMHE, Kelder A, Oudshoorn-van Marsbergen L, Scholten WJ, Snel AN, Bachas C, Tettero JM, Breems DA, Fischer T, Gjertsen BT, Griškevičius L, Juliusson G, van de Loosdrecht AA, Maertens JA, Manz MG, Pabst T, Passweg JR, Porkka K, Valk PJM, Gradowska P, Löwenberg B, de Leeuw DC, Janssen JJWM, Ossenkoppele GJ, Cloos J. Ngai LL, et al. Among authors: tettero jm. Blood. 2023 May 25;141(21):2657-2661. doi: 10.1182/blood.2022019160. Blood. 2023. PMID: 36898087 Free PMC article.
Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis.
Tettero JM, Al-Badri WKW, Ngai LL, Bachas C, Breems DA, van Elssen CHMJ, Fischer T, Gjertsen BT, van Gorkom GNY, Gradowska P, Greuter MJE, Griskevicius L, Juliusson G, Maertens J, Manz MG, Pabst T, Passweg J, Porkka K, Löwenberg B, Ossenkoppele GJ, Janssen JJWM, Cloos J. Tettero JM, et al. Front Oncol. 2022 Oct 10;12:999822. doi: 10.3389/fonc.2022.999822. eCollection 2022. Front Oncol. 2022. PMID: 36300090 Free PMC article.
15 results